Research programme: autism therapeutic - Cellceutix

Drug Profile

Research programme: autism therapeutic - Cellceutix

Alternative Names: Autism compound - Cellceutix; KM-391

Latest Information Update: 07 Oct 2015

Price : $50

At a glance

  • Originator Unknown
  • Developer Cellceutix
  • Class Small molecules
  • Mechanism of Action Serotonin uptake modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Autistic disorder

Most Recent Events

  • 16 May 2012 Preclinical development is ongoing for Austistic disorder in USA
  • 28 Mar 2011 Cellceutix signs a Confidential Disclosure Agreement with an undisclosed pharmaceutical company for the development of KM-391 in Autism
  • 23 Jun 2010 Preclinical pharmacodynamics data released by Cellceutix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top